Karyopharm Therapeutics Inc. (KPTI) News

Karyopharm Therapeutics Inc. (KPTI): $5.64

0.02 (+0.36%)

POWR Rating

Component Grades













Filter KPTI News Items

KPTI News Results

Date Symbol Company Title Start End Change POWR Rating
Loading, please wait...

KPTI News Highlights

  • KPTI's 30 day story count now stands at 29.
  • Over the past 29 days, the trend for KPTI's stories per day has been choppy and unclear. It has oscillated between 1 and 10.
  • DRUG, CELZ and MET are the most mentioned tickers in articles about KPTI.

Latest KPTI News From Around the Web

Below are the latest news stories about Karyopharm Therapeutics Inc that investors may wish to consider to help them evaluate KPTI as an investment opportunity.

The Petri Dish: Moderna, Thermo become long-term partners; Karyopharm medical chief departs

The Massachusetts life sciences industry is rife with companies developing drugs and devices to tackle serious diseases, inking new partnership deals, raising money, expanding facilities and more.

Yahoo | February 24, 2022

HOOKIPA, Nuvectis top healthcare gainers; Allarity, Homology Medicines lead losers' pack

Gainers: HOOKIPA Pharma (NASDAQ:HOOK) +18%. Nuvectis Pharma (NASDAQ:NVCT) +16%. Ocugen (NASDAQ:OCGN) +14%. Privia Health (NASDAQ:PRVA) +12%. IMARA (NASDAQ:IMRA) +11%. Losers: Allarity Therapeutics (NASDAQ:ALLR) -29%. Homology Medicines (NASDAQ:FIXX) -27%. Karyopharm Therapeutics (NASDAQ:KPTI) -25%. Modular Medical (NASDAQ:MODD) -14%. Mainz Biomed (NASDAQ:MYNZ) -11%....

Seeking Alpha | February 22, 2022

Why Are Karyopharm Shares Plunging Today?

Karyopharm Therapeutics Inc (NASDAQ: KPTI) revealed that executive vice president and chief medical officer Jatin Shah departs for "other professional opportunities." While CEO Paulson looks for Shah's replacement, he has recruited two Big Pharma vets to take up key posts on the team: Patricia Judson, who led women's oncology at GlaxoSmithKline and AstraZeneca, will become the SVP of medical strategy. From AbbVie, Amgen, and Eli Lilly, Stuart Poulton has been appointed SVP of strategy and portfo

Yahoo | February 22, 2022

Here's Why Karyopharm Therapeutics Is Sliding on Tuesday

Investors aren't pleased with the surprise departure of the company's chief medical officer.

Yahoo | February 22, 2022

Karyopharm Announces Changes to Its Clinical Leadership Team

Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced changes to its clinical leadership team, including the appointment of Patricia Judson, M.D., as Senior Vice President of Medical Strategy and Stuart Poulton as Senior Vice President of Strategy and Portfolio Management. In addition, Jatin Shah, M.D. Executive Vice President and Chief Medical Officer has stepped down to pursue other professional opportunities, b

Yahoo | February 22, 2022

Thinking about buying stock in Creative Medical Technology, Nu Holdings, Barrick Gold, Opendoor Technologies, or Karyopharm Therapeutics?

NEW YORK , Feb. 18, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for CELZ, NU, GOLD, OPEN, and KPTI. … Full story available on Benzinga.com

Benzinga | February 18, 2022

MTEK, QDEL and BLZE are among mid-day movers

Gainers: HOOKIPA Pharma (HOOK) +26%.Maris-Tech (MTEK) +18%.Karyopharm Therapeutics (KPTI) +18%.Creative Medical Technology Holdings (CELZ) +15%.Cambium Networks (CMBM) +16%.Inotiv…

Seeking Alpha | February 18, 2022

Karyopharm to Participate at 11th Annual SVB Leerink Global Healthcare Conference

Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that Richard Paulson, President and Chief Executive Officer of Karyopharm, will participate in a fireside chat at the 11th Annual SVB Leerink Global Healthcare Conference. The conference is being conducted in a virtual format and the fireside chat will take place on Friday, February 18, 2022 at 1:40 p.m. ET.

Yahoo | February 11, 2022

The Petri Dish: Syndax, Checkmate get new CEOs; Biogen stays in biosimilars game

While some in the life sciences industry create drugs and devices to tackle the Covid-19 pandemic, their colleagues are busy as ever raising money, testing new drugs, expanding facilities and more.

Yahoo | February 10, 2022

Analysts Offer Insights on Healthcare Companies: Karyopharm Therapeutics (KPTI) and Akero Therapeutics (AKRO)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Karyopharm Therapeutics (KPTI – Research Report) and Akero Therapeutics (AKRO – Research Report) with bullish sentiments. Karyopharm Therapeutics (KPTI) H.C. Wainwright analyst Edward White maintained a Buy rating on Karyopharm Therapeutics today and set a price target of $26.00. The company's shares closed last Wednesday at $9.13. According to TipRanks.

Brian Anderson on TipRanks | February 9, 2022

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.5232 seconds.